India Continuous Glucose Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The Indian Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 23.8%, reaching USD 16.0 million in 2031 from USD 5.5 million in 2026.

Key Highlights

Market Overview

The commercial environment is shaped by India's expanding diabetes burden and greater clinical acceptance of continuous monitoring. According to the International Diabetes Federation, India remains one of the world's largest populations living with diabetes, while national health initiatives continue to encourage earlier diagnosis and long-term disease management. These trends are increasing demand for technologies that support treatment optimization, improve patient adherence, and reduce complications associated with poor glycemic control.

Purchasing decisions vary across buyer groups. Large hospitals and diabetes specialty centers prioritize clinical accuracy, interoperability with hospital information systems, physician reporting capabilities, and after-sales technical support. Individual users place greater weight on sensor comfort, replacement frequency, smartphone compatibility, ease of calibration, and recurring ownership costs. As reimbursement remains limited for many patients, affordability continues to influence product selection, particularly outside metropolitan areas.

Competition extends beyond device performance. Suppliers increasingly differentiate themselves through digital applications, cloud-based data sharing, physician engagement programs, patient education initiatives, and distribution partnerships. Revenue generation therefore depends not only on hardware sales but also on recurring sensor replacement cycles, software integration, clinical services, and customer retention throughout long-term diabetes management.

Key Market Indicators

Key indicator: India has one of the world's largest diabetes populations according to the International Diabetes Federation.

Commercial meaning: Long-term disease management creates sustained demand for monitoring technologies rather than one-time device purchases.

Market Drivers

Expansion of intensive diabetes management among insulin-dependent patients.

Clinical practice is increasingly shifting from episodic glucose testing toward continuous monitoring for patients requiring intensive insulin therapy. Physicians rely on CGM data to evaluate glucose variability, nocturnal hypoglycemia, and treatment response with greater precision than conventional self-monitoring. International clinical guidelines and evidence supporting time-in-range measurements are encouraging wider adoption among endocrinologists. Manufacturers are responding by expanding professional education programs, improving sensor accuracy, and introducing devices with longer wear duration, allowing healthcare providers to integrate CGM more routinely into diabetes treatment protocols.

Growth of home-based disease management supported by digital health infrastructure.

Patients increasingly prefer managing chronic conditions outside hospital settings, particularly for long-term diabetes care. India's expanding digital health ecosystem, higher smartphone penetration, and teleconsultation services allow physicians to review glucose trends remotely and adjust treatment without frequent in-person visits. This model improves patient convenience while supporting continuous clinical supervision. Suppliers are investing in mobile applications, cloud connectivity, caregiver notification features, and physician dashboards to strengthen user engagement and encourage sustained sensor utilization throughout the treatment cycle.

Improved clinical awareness of glycemic variability and diabetes complications.

Healthcare providers are placing greater emphasis on preventing long-term complications associated with uncontrolled glucose levels, including cardiovascular disease, kidney impairment, neuropathy, and diabetic retinopathy. Continuous monitoring enables earlier identification of glucose excursions that may not be detected through periodic blood glucose testing or glycated hemoglobin measurements alone. Hospitals and diabetes clinics increasingly use CGM during treatment optimization, pregnancy management, and complex insulin adjustment, supporting broader institutional demand across specialized diabetes care services.

Expansion of organized diabetes care and specialty healthcare networks.

Private hospital groups, dedicated diabetes clinics, and multispecialty healthcare providers are expanding specialized endocrine services across metropolitan and tier-two cities. These institutions increasingly incorporate advanced monitoring technologies into standardized diabetes care pathways to improve clinical outcomes and patient retention. Manufacturers are strengthening commercial partnerships with hospitals, physician networks, and distributors while expanding training programs for healthcare professionals. Better clinical familiarity with CGM technology is gradually lowering adoption barriers and improving physician confidence in recommending continuous monitoring.

Market Restraints and Challenges

High recurring ownership costs restrict wider patient adoption.

Although initial device availability has improved, recurring expenditure on disposable sensors remains one of the largest barriers to broader adoption in India. Unlike conventional glucose meters, CGM systems require periodic sensor replacement, increasing lifetime ownership costs for patients without comprehensive reimbursement. Price sensitivity is particularly pronounced among middle-income households and patients requiring lifelong monitoring. Manufacturers continue exploring localized distribution strategies, patient assistance programs, and product portfolio diversification to improve affordability while maintaining commercial viability.

Limited reimbursement and uneven insurance coverage.

Private insurance coverage for continuous glucose monitoring remains inconsistent, while public reimbursement mechanisms remain limited for routine outpatient diabetes monitoring. As a result, many purchasing decisions depend directly on household healthcare spending rather than institutional funding. Hospitals may recommend CGM technology based on clinical value, but patient acceptance frequently depends on affordability rather than medical necessity alone. Broader reimbursement policies could materially improve adoption across larger patient populations during the forecast period.

Uneven specialist availability across smaller cities and rural healthcare systems.

Successful CGM utilization requires physician interpretation, patient education, and ongoing therapy adjustments. Access to endocrinologists and diabetes educators remains concentrated in larger urban centers, limiting optimal device utilization in many regions. General practitioners may have limited experience interpreting continuous glucose datasets, reducing confidence in prescribing advanced monitoring systems. Manufacturers increasingly address this gap through physician training initiatives, digital education platforms, and technical support programs, although expanding clinical expertise remains a gradual process.

Data integration and digital interoperability remain evolving requirements.

Healthcare providers increasingly expect monitoring devices to integrate with electronic medical records, telemedicine platforms, insulin delivery systems, and clinical decision-support software. Differences in software architecture, cybersecurity standards, and data-sharing protocols can complicate integration across healthcare providers. Hospitals evaluating digital health investments increasingly assess interoperability alongside clinical performance before procurement decisions are finalized. Suppliers therefore continue investing in software development, cybersecurity enhancements, and cloud-based connectivity to strengthen compatibility across India's evolving digital healthcare ecosystem.

Major Segment Analysis

Diabetes Patients

The diabetes patients segment represents the primary commercial application for continuous glucose monitoring in India because long-term glucose management requires regular monitoring, treatment adjustment, and sustained patient engagement. Individuals with Type 1 diabetes, insulin-dependent Type 2 diabetes, gestational diabetes, and patients experiencing frequent hypoglycemic episodes derive the greatest clinical value from continuous glucose data. Hospitals and endocrinologists increasingly recommend CGM for patients requiring intensive insulin therapy, where treatment decisions depend on identifying daily glucose fluctuations rather than isolated blood glucose measurements.

Purchasing priorities within this segment extend beyond clinical accuracy. Patients evaluate sensor wear duration, comfort, smartphone compatibility, replacement costs, data-sharing capability with caregivers and physicians, and after-sales technical support before selecting a device. Suppliers therefore compete through broader digital ecosystems rather than sensor performance alone, integrating mobile applications, cloud-based reporting, and remote physician access. Although the critical care application continues to expand within hospital settings, recurring sensor replacement among diabetes patients generates a more stable long-term revenue opportunity and strengthens customer retention throughout chronic disease management.

Competitive Landscape

Competition in India's continuous glucose monitoring market is technology-driven but increasingly influenced by service capability, physician engagement, and distribution reach. Abbott Laboratories, Dexcom, Inc., Medtronic plc, Roche Diabetes Care, Inc., Ypsomed AG, Senseonics Holdings, Inc., and ARKRAY Inc. compete through different combinations of sensor performance, digital health integration, clinical evidence, and support services rather than price alone.

Established multinational suppliers benefit from extensive regulatory experience, physician relationships, and recognized diabetes care portfolios. Companies continue expanding mobile applications, cloud-based reporting platforms, and interoperability with insulin delivery systems to improve patient retention and strengthen recurring sensor sales. Distribution partnerships with hospitals, specialty clinics, pharmacies, and diabetes care providers remain central to commercial expansion because physician recommendation strongly influences device selection. Market entry barriers include regulatory approval requirements, clinical validation, after-sales service capability, and the recurring investment needed to maintain sensor manufacturing quality and software development.

Recent Developments

• March 2026: TRACKY expanded its digital health ecosystem in India by collaborating with TatvaCare, integrating real-time continuous glucose monitoring with broader digital health platforms for managing diabetes and chronic kidney disease.

• August 2025: Abbott introduced the FreeStyle Libre 2 Plus continuous glucose monitoring sensor in India, offering continuous minute-by-minute glucose readings, optional real-time alarms, and up to 15 days of wear for improved diabetes management.

• June 2025: Abbott and MSD Pharmaceuticals announced a strategic distribution partnership for MSD's oral anti-diabetic medicines in India, complementing Abbott's diabetes care ecosystem, including its continuous glucose monitoring solutions and integrated patient management offerings.

• June 2025: DrStore introduced TRACKY, launching India’s first low-cost, Bluetooth-enabled CGM. Priced at ?5,999, it provides scan-free glucose monitoring to make diabetes management more accessible.

Regulatory and Policy Environment

India's regulatory framework for continuous glucose monitoring continues to evolve alongside broader reforms supporting digital healthcare, medical device regulation, and non-communicable disease management. Medical devices are regulated under the Medical Device Rules administered by the Central Drugs Standard Control Organization (CDSCO), requiring manufacturers to comply with registration, quality management, labeling, and post-market surveillance obligations before commercialization.

National initiatives addressing non-communicable diseases are increasing diabetes screening and encouraging earlier diagnosis through public healthcare systems. The National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), formerly NPCDCS, supports screening, referral, and long-term management of diabetes across primary and secondary healthcare facilities. The Ayushman Bharat Digital Mission also promotes digital health records and interoperable healthcare systems, creating a more supportive environment for connected monitoring technologies. Although routine reimbursement for CGM remains limited, policy emphasis on preventive care and digital health infrastructure is gradually improving the conditions necessary for wider adoption.

Outlook and Strategic Implications

Commercial expansion through 2031 will depend less on first-time device sales and more on sustained patient engagement, physician confidence, recurring sensor replacement, and broader integration with digital diabetes management. As healthcare providers increasingly focus on improving long-term clinical outcomes, continuous glucose monitoring is expected to become more deeply embedded within structured diabetes care pathways across hospitals, specialty clinics, and home-based care.

Several strategic priorities are likely to shape market performance during the forecast period:

• Manufacturers are expected to expand localized distribution, strengthen physician education, and improve affordability through broader product portfolios.

• Healthcare providers will increasingly evaluate CGM platforms based on clinical evidence, interoperability, and long-term patient adherence rather than hardware specifications alone.

• Technology providers will continue investing in cloud connectivity, remote monitoring, cybersecurity, and integration with digital health platforms.

• Policymakers and healthcare administrators may improve market accessibility by expanding diabetes screening programs, strengthening digital health infrastructure, and encouraging evidence-based chronic disease management.

The market is therefore expected to remain closely aligned with India's broader efforts to improve chronic disease management, expand access to digital healthcare, and reduce the long-term clinical and economic burden associated with diabetes.

India Continuous Glucose Monitoring Market Scope: